CA-CLOUDBLUE
31.3.2021 15:02:06 CEST | Business Wire | Press release
CloudBlue, a leading cloud ecosystem technology company, has completed the acquisition and integration of Harmony Business Systems (HBS). Its comprehensive professional services automation (PSA) and revenue management software is now a complement to CloudBlue’s portfolio of services designed to simplify and accelerate resellers’ transition to an everything-as-a-service business.
As a CloudBlue company, UK-based HBS will independently operate HarmonyPSA, to serve customers around the world. Launched over a decade ago and with customers in 15 countries, the platform features multi-language support and enjoys one of the highest customer satisfaction ratings in the industry. It was purpose-built to manage any type of service by unifying sales, operations and finance functions. HarmonyPSA combines CRM, ticketing, storefront, lead generation, assisted sales, and vendor competency and incentive programs into a single solution as a quote to cash and accounting system. It is now available for the first time on the UK Ingram Micro Cloud Marketplace.
Resellers will have a dedicated instance to quickly find and procure hardware and software, pay-as-you-go and recurring subscription cloud technologies across various online marketplaces, including Ingram Micro Online and Ingram Micro Cloud Marketplace. HarmonyPSA automates the billing process and provides accurate, real-time views of customers’ contracts, projects and profitability.
“The acquisition of Harmony is a direct response to our MSP partners’ requests to help them quickly transform and grow a cloud services business with less risk,” said Nimesh Davé, president of CloudBlue and Ingram Micro Cloud. “We are delighted to have the Harmony team join our CloudBlue community as we expand our technology offerings.”
“We’re extremely excited to join the CloudBlue family to capitalize on our shared commitment of driving growth for our customers,” said Steve Powell, co-founder and CTO of Harmony Business Systems. “By working together, we will dramatically scale our customer base and expand our offering across various marketplaces.”
Stephen Robitaille, director of sales operations at intlx Solutions and a customer of HarmonyPSA, is enthusiastic about the platform's ability to automatically create purchase orders and generate unique reports that track project profitability on all aspects of the business. "It's made my work much easier and our business much more efficient."
More information on HarmonyPSA and how it helps accelerate the digital transformation of reseller partners is available at www.harmonypsa.com .
About CloudBlue
CloudBlue provides a hyperscale platform with hypergrowth products and services that allows providers to launch and manage an omni-product, multi-tier and multi-channel marketplace. With CloudBlue, providers can access and capitalize on a hyperconnected ecosystem of 200+ top-selling vendors, 200+ leading brands and more than 80,000 partners globally. Many of the world’s best-known software and SaaS vendors, digital service providers, technology distributors, tech manufacturers, managed services providers and value-added resellers rely on CloudBlue’s leading CloudBlue Commerce and CloudBlue Connect platforms to automate, aggregate and sell both their own cloud services as well as those from third-party vendors. CloudBlue powers more than 200 of the world’s largest provider cloud marketplaces, which collectively represent more than 30 million enterprise cloud subscriptions. More at www.cloudblue.com .
About Harmony Business Systems
Harmony Business Systems Ltd., a CloudBlue company, is the company behind HarmonyPSA, the most complete cloud professional services automation (PSA) software on the market. Purpose-built with functionality to cater to even the most complex needs of MSPs, VARs, ISVs and Professional Services Organizations, HarmonyPSA truly is the next-generation PSA system built for today’s Modern Service Provider. Amplified by CloudBlue’s powerful cloud services automation platform, HarmonyPSA empowers services organizations to scale recurring channel revenue and diminish operational complexity via its advanced product suite, which includes automated billing and reconciliation, real-time profitability analysis, an industry-leading customer support center and network operations center (NOC), and much more. To learn more, visit www.harmonypsa.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005021/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom